Pharma

Pharmalot

Biogen’s latest Alzheimer’s drug data may look good, but is it enough for FDA approval?

By Ed Silverman

Pharmalot

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

By Ed Silverman

Pharmalot

Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen

By Ed Silverman

Pharmalot

The use of antibiotics in food-producing livestock continues to drop in most of Europe

By Ed Silverman

Pharmalot

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

By Ed Silverman

Pharmalot

Sanofi pulls Zantac from the U.S., joining a growing list of companies recalling heartburn meds

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Sanders, other lawmakers say FDA is not being transparent about Takeda’s recall of lifesaving drug

By Ed Silverman

Pharmalot

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

By Ed Silverman

Pharmalot

CSL sues a former employee and rival over alleged theft of trade secrets

By Ed Silverman

Pharmalot

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

By Ed Silverman

Pharmalot

Most state Medicaid programs continue to restrict access to hepatitis C medicines

By Ed Silverman

Pharmalot

Pharmalittle: Opioid trial underway as distributors try to settle; patients beg DEA to reconsider opioid production cuts

By Ed Silverman

Intermountain Healthcare - central pharmacy

Pharmalot

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

By Ed Silverman

Pharmalot

Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids

By Ed Silverman

Pharmalot

Most Americans back various ideas to lower drug costs, but some fear impeachment will get in the way

By Ed Silverman

Pharmalot

Congressional Budget Office says Pelosi drug pricing bill could save $345 billion

By Ed Silverman

Pharmalot

FDA bid to bolster generic competition and combat shortages isn’t working — yet

By Ed Silverman

Pharmalot

Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial

By Ed Silverman

Pharmalot

Sun Pharma is accused of distributing medicines in Washington state without a license

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sackler role in opioid crisis to be debated in court; J&J legal strategy shows risks

By Ed Silverman

A photo of rifampin pills used to treat Tuberculosis.

Pharmalot

Doctors Without Borders demands drug makers lower their prices for TB treatments

By Ed Silverman

Pharmalot

Teamsters chastise Cardinal Health over a board member tied to opioid fines

By Ed Silverman

Pharmalot

Pharmalittle: Democratic candidates eye ‘march-in rights’ to lower drug prices; racial disparities drive NIH funding

By Ed Silverman

A U.K. official says the National Health Service is getting closer to a deal with Vertex

More new medicines benefited from publicly supported research than you may have thought

Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

Biogen’s latest Alzheimer’s drug data may look good, but is it enough for FDA approval?

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen

The use of antibiotics in food-producing livestock continues to drop in most of Europe

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

Sanofi pulls Zantac from the U.S., joining a growing list of companies recalling heartburn meds

Up and down the ladder: The latest comings and goings

Sanders, other lawmakers say FDA is not being transparent about Takeda’s recall of lifesaving drug

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

CSL sues a former employee and rival over alleged theft of trade secrets

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

Most state Medicaid programs continue to restrict access to hepatitis C medicines

Pharmalittle: Opioid trial underway as distributors try to settle; patients beg DEA to reconsider opioid production cuts

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids

Most Americans back various ideas to lower drug costs, but some fear impeachment will get in the way

Congressional Budget Office says Pelosi drug pricing bill could save $345 billion

FDA bid to bolster generic competition and combat shortages isn’t working — yet

Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial

Sun Pharma is accused of distributing medicines in Washington state without a license

Up and down the ladder: The latest comings and goings

Pharmalittle: Sackler role in opioid crisis to be debated in court; J&J legal strategy shows risks

Doctors Without Borders demands drug makers lower their prices for TB treatments

Teamsters chastise Cardinal Health over a board member tied to opioid fines

Pharmalittle: Democratic candidates eye ‘march-in rights’ to lower drug prices; racial disparities drive NIH funding